ABIONYX Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ABIONYX Pharma's earnings are forecast to decline at 23.4% per annum while its annual revenue is expected to grow at 40.7% per year. EPS is expected to decline by 13.8% per annum.

Wichtige Informationen

-23.4%

Wachstumsrate der Gewinne

-13.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum8.4%
Wachstumsrate der Einnahmen40.7%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert22 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Jun 26
Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Oct 12
Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Jan 27
Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:ABNX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202612-7-7-71
12/31/20257-9-9-91
12/31/20245-6-6-61
6/30/20245-3-3-3N/A
3/31/20245-3-3-3N/A
12/31/20235-4-4-4N/A
9/30/20235-4N/AN/AN/A
6/30/20235-4-2-2N/A
3/31/20235-4-3-3N/A
12/31/20225-4-4-3N/A
9/30/20224-5N/AN/AN/A
6/30/20223-6-6-6N/A
3/31/20222-6-6-6N/A
12/31/20211-6-7-7N/A
9/30/20210-5N/AN/AN/A
6/30/20210-4-6-5N/A
3/31/20210-3-3-3N/A
12/31/2020N/A-2-1-1N/A
9/30/2020N/A-2-1-1N/A
6/30/2020N/A-200N/A
3/31/2020N/A0-2-2N/A
12/31/2019N/A2-4-4N/A
9/30/201901-5-5N/A
6/30/201900-6-6N/A
3/31/20190-3-6-6N/A
12/31/20180-6-6-6N/A
9/30/20180-7-6-6N/A
6/30/2018N/A-8-7-7N/A
3/31/2018N/A-6N/A-8N/A
12/31/2017N/A-5N/A-9N/A
9/30/2017N/A-8N/A-11N/A
6/30/2017N/A-11N/A-13N/A
3/31/2017N/A-18N/A-16N/A
12/31/2016N/A-25N/A-19N/A
9/30/2016N/A-25N/A-19N/A
6/30/2016N/A-24N/A-19N/A
3/31/2016N/A-20N/A-16N/A
12/31/2015N/A-17N/A-14N/A
9/30/2015N/A-13N/A-11N/A
6/30/2015N/A-10N/A-8N/A
3/31/2015N/A-8N/A-6N/A
12/31/2014N/A-7N/A-3N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ABNX is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: ABNX is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: ABNX is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: ABNX's revenue (40.7% per year) is forecast to grow faster than the French market (5.6% per year).

Hohe Wachstumseinnahmen: ABNX's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken